|
|
|
|
|
02.03.26 - 14:03
|
Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:...
|
|
|
|
|
|
|
|
|
|
|
|
|
18.12.25 - 14:03
|
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT....
|
|
|
16.12.25 - 15:09
|
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer (Business Wire)
|
|
|
PITTSBURGH--(BUSINESS WIRE)--#CytoAgents--CytoAgents, Inc. a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation, announced today the appointment of Dr. Johannes Wolff, MD, PhD, as Chief Medical Officer (CMO) and Michael D. Howell, PhD, as Chief Scientific Officer (CSO).
Dr. Johannes Wolff, MD, PhD, Chief Medical Officer
Dr. Wolff brings over three decades of distinguished leadership in academic medicine and the pharmaceutical industry, with deep expertise in clinical trial strategy, drug development, and medical affairs. Originally trained as a pediatric hematologist-oncologist, Dr. Wolff has held senior roles in both academic and industry settings, including Vice President of Clinical Development at Replimune, Senior Medical Director at AbbVie and Novartis, and department chair positions at leading institutions such as Cleveland Clinic and Tufts Medical Center. He has led successful Investigational New Drug applications, pivo...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
